• MediaValet (MVP) has announced a non-brokered private placement for gross proceeds of $3.0 million
  • The offering consists of 2,307,700 units priced at $1.30 per unit and has been fully subscribed to by company insiders
  • Shen Capital Partners Inc.  has agreed to subscribe for 1,923,077 units, and CFO David Miller has agreed to subscribe for 384,623 units
  • MediaValet Inc develops enterprise cloud software for companies in a variety of industries
  • MediaValet Inc. (MVP) opened trading at C$1.11

MediaValet (MVP) has announced a non-brokered private placement to raise $3.0 million.

The offering consists of 2,307,700 units priced at $1.30 per unit. Each unit consists of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional common share at a price of $1.50 for a period of 36 months from the closing of the offering.

The entire offering is being subscribed to by company insiders. Shen Capital Partners Inc. has agreed to subscribe for 1,923,077 units, and CFO David Miller has agreed to subscribe for 384,623 units. Shen Capital currently holds 7,677,786 MediaValet shares.

The net proceeds will be used for general working capital. 

All securities issued are subject to a statutory four-month hold period.

MediaValet Inc develops enterprise cloud software. It manages media assets for organizations across various industries, including manufacturing, healthcare, media and entertainment, high-tech, natural resources, retail, travel, and hospitality.

MediaValet Inc. (MVP) opened trading at C$1.11.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.